stockrow
Friday 6 November 2026
Export LUCY’s income statement to Excel — free account
Innovative Eyewear, Inc.
LUCY Healthcare Medical Instruments & Supplies
Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024.
- Revenue
- +74.5%
- EPS
- +60.6%
- Free cash flow
- +9.61%
- Total debt
- −92.4%
Quarter to June 2026, against a year earlier
0.82
0.00
0.00%
Follow LUCY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 1 | 1 | 2 | 3 | 3 | +115.7% | 7 | 22 | — | +187.5% | |
| Gross margin, % | — | — | — | — | (30.35) | 21.47 | (8.53) | (10.35) | 13.15 | 21.32 | 22.78 | +51.7 pt | ||||||
| EBT | — | — | — | — | (1) | (3) | (6) | (7) | (8) | (8) | (8) | +58.1% | ||||||
| EBT margin, % | — | — | — | — | (1,347.72) | (469.74) | (861.14) | (578.17) | (474.61) | (285.20) | (225.28) | +1,062.5 pt | ||||||
| Net income | — | — | — | — | (1) | (3) | (6) | (7) | (8) | (8) | (8) | +58.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.39 | 2.63 | 1.72 | 1.88 | 1.09 | 0.67 | 0.53 | +11.6% | |||||
| Earnings | — | — | — | — | (5.19) | (12.40) | (14.79) | (10.87) | (5.19) | (1.90) | (1.35) | (18.2%) | ||||||
| Cash flow | — | — | — | — | (0.27) | (4.63) | (8.40) | (9.41) | (4.51) | (1.82) | (1.12) | +46.3% | ||||||
| Capex | — | — | — | — | (0.40) | (0.45) | (0.57) | (0.41) | (0.32) | (0.06) | (0.02) | (30.9%) | ||||||
| Free cash flow | — | — | — | — | (0.67) | (5.08) | (8.97) | (9.81) | (4.82) | (1.88) | (1.14) | +23.0% | ||||||
| Book value | — | — | — | — | (3.75) | 0.79 | 10.48 | 9.07 | 6.08 | 2.27 | 1.08 | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 1 | 1 | 4 | 5 | +93.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 48.32 | 48.32 | 12.37 | 4.79 | 4.50 | 1.50 | 1.56 | 20.0 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 2.03 | 0.99 | 0.81 | 0.44 | 0.77 | 0.7 | ||||||
| EV/Sales | — | — | — | — | 50.90 | 50.90 | 7.02 | 1.12 | (0.06) | (0.91) | 0.48 | 18.2 | ||||||
| EV/FCF | — | — | — | — | (17.27) | (17.27) | (1.35) | (0.21) | 0.01 | 0.32 | (0.22) | (6.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (3) | (6) | (7) | (7) | (7) | +182.7% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +33.4% | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | (3) | (6) | (7) | (8) | (7) | +137.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (1) | 0 | 4 | 5 | 9 | 8 | 6 | n/m | |||||
| Net debt | — | — | — | — | 1 | 0 | (4) | (4) | (8) | (6) | (4) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | (1) | 0 | 4 | 6 | 9 | 9 | 7 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (626.77) | (206.08) | (122.17) | (96.74) | (75.99) | (79.21) | (76.0) pt | |||||
| ROIC | — | — | — | — | (2,702.33) | (480.61) | (704.56) | (337.01) | (315.25) | (205.50) | (168.07) | +2,496.8 pt | ||||||
| ROE | — | — | — | — | 0.00 | 1,868.41 | (268.52) | (139.06) | (106.00) | (83.60) | (84.58) | (83.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 9 | 9 | 11 | 11 | 13 | — | +9.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.08 | 0.07 | 0.10 | 0.15 | 0.20 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Innovative Eyewear, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLSS Milestone Scientific, Inc. | $27.1M | — (loss-making) | — (loss-making) | +22.27% (above 0%: growing) | n/m | +66.68% (above 0%: growing) | 67.24% | (37.37%) | Compare |
| RVP Retractable Technologies, Inc. | $16.9M | — (loss-making) | 11.1× | −31.07% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 2.65% | (71.46%) | Compare |
| BNGO Bionano Genomics, Inc. | $15.4M | — (loss-making) | — (loss-making) | +21.36% (above 0%: growing) | n/m | −33.93% (below 0%: shrinking) | 52.80% | (88.34%) | Compare |
| NXGL NexGel, Inc. | $12.7M | — (loss-making) | — (loss-making) | +27.81% (above 0%: growing) | n/m | −432.32% (below 0%: shrinking) | 30.09% | (67.96%) | Compare |
| FEMY Femasys Inc. | $11.0M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +11.29% (above 0%: growing) | 57.08% | (1,526.79%) | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $10.4M | — | — | — | — | — | — | — | Compare |
| RGNT Regentis Biomaterials Ltd. | $8.2M | — | — | — | — | −132.79% (below 0%: shrinking) | — | — | Compare |
| LUCY Innovative Eyewear, Inc. | $7.2M | — (loss-making) | — | +74.46% (above 0%: growing) | n/m | +9.61% (above 0%: growing) | 24.00% | (168.73%) | |
| MHUAF Meihua International Medical Technologies Co., Ltd. | $4.3M | — | — | — | — | −61.55% (below 0%: shrinking) | 35.48% | 0.00% | Compare |
| Median of peers | $11.8M | — | — | +21.36% | — | −33.93% | 44.14% | (69.71%) |
Pay and ownership Proxy statement filed 5 October 2026
Ownership
Directors and executive officers, together
1.76%
Vladimir and Angelica Galkin
11.48%
Intracoastal Capital LLC
9.99%
Kelly Jospeh Chapman
5.17%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement